Management of Hypotension Associated with Tenecteplase
Key Distinction: TNK vs. Streptokinase
- The European Society of Cardiology recommends that tenecteplase (TNK) is NOT typically associated with hypotension, unlike streptokinase which commonly causes this complication 1, 2, 3, 4
- TNK is a fibrin-specific agent with significantly lower rates of non-cerebral bleeding and better safety profile compared to non-fibrin-specific agents like streptokinase 2, 5, 4
Immediate Management Protocol
- If hypotension develops during TNK administration, the American Heart Association recommends to stop the infusion immediately and position the patient flat with legs elevated 1, 2
- The American College of Cardiology suggests assessing for alternative causes of hypotension, including cardiogenic shock, right ventricular infarction, bleeding complications, and concurrent medications or allergic reactions 5, 2, 4
- Pharmacologic intervention with atropine for bradycardia-associated hypotension or intravenous volume expansion with crystalloids for hypovolemia may be necessary 1, 2, 4
Post-TNK Monitoring Requirements
- The American College of Cardiology recommends monitoring continuously for 60-180 minutes after TNK administration for ST-segment resolution, hemodynamic stability, cardiac rhythm, and clinical symptom relief 5, 6
- All patients receiving TNK should be transferred to a PCI-capable center for early angiography (2-24 hours post-lysis if successful, immediately if failed reperfusion) 4, 6
Risk Factors and Prevention
- The European Society of Cardiology notes that patients at higher risk for complications, including bleeding, are those with advanced age, lower weight, and female gender 1, 2, 3
- Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg) is an absolute contraindication for TNK administration 8, 5, 6
- The weight-based dosing of TNK reduces complications, with recommended doses of 30-50 mg based on patient weight 8, 5, 7